18 May 2021 : Database Analysis
Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer
Yinqi Gao1ABCE, Xuelong Wang2AC, Shihui Li1CE, Zhiqiang Zhang1CE, Xuefei Li1CE, Fangcai Lin1AE*DOI: 10.12659/MSM.930025
Med Sci Monit 2021; 27:e930025
Table 2 Clinical characteristics of the patients in the training and validation cohorts.
| Variables | Training cohortTCGA-TNBCN(%) | Validation CohortGSE141441N(%) | Validation CohortGSE78754N(%) |
|---|---|---|---|
| Normal | – | – | – |
| Tumor | 114 (100%) | 130 (100%) | 63 (100%) |
| (years; range) | 55 (29–84) | 57 (32–92) | 54 (30–83) |
| I | 19 (16.7%) | 44 (33.8%) | – |
| II | 73 (64.0%) | 72 (55.4%) | – |
| III | 20 (17.5%) | 14 (10.8%) | – |
| IV | 2 (1.8%) | 0 (0.0%) | – |
| Metastasis | 71 (62.3%) | – | – |
| Non-netastasis | 43 (37.7%) | – | – |
| Alive | 100 (87.7%) | – | 20 (31.7%) |
| Dead | 14 (12.3%) | – | 43 (68.3%) |
| Yes | – | 68 (52.3%) | – |
| No | – | 62 (47.7%) | – |